Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress July 1, 2021
Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer Cells May 13, 2021
Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Meeting I April 12, 2021
Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 April 9, 2021
Affimed to Report Full Year 2020 Financial Results & Corporate Update on April 15, 2021 April 8, 2021
